Comparison of vaginal and oral misoprostol, for the induction of labour in women with intra-uterine foetal death.
OBJECTIVE
To compare the efficacy of vaginal and oral misoprostol for the induction of labour in women with intra-uterine foetal death (IUFD).


METHODS
A prospective randomised clinical trial, comparing 200 microg oral and 200 microg vaginal misoprostol, six hourly for a maximum of four doses for the induction of labour in women with IUFD.


METHODS
Ga-Rankuwa hospital (Department of Obstetrics and Gynaecology), Pretoria, South Africa. It is a tertiary institution serving predominantly black indigenous population.


METHODS
The primary outcome measure was the induction to delivery time, and secondary outcome measures were the number of patients requiring augmentation with oxytocin and all complications were noted.


RESULTS
Twenty women were randomised to the vaginal route and 18 to the oral route. The induction to delivery time was shorter with vaginal misoprostol (13.5 +/- 8.3 hrs) compared to oral misoprostol (21.4 +/- 13.9 hrs; p < 0.05). There was no significant difference in the amount of misoprostol needed to achieve successful induction in the two groups. More women (10/18) who received oral misoprostol required oxytocin augmentation to complete the induction of labour compared with 4/20 women in the vaginal group (p < 0.05; Odds Ratio 2.8; 95% Cl 1.36 - 4.24). There were no cases of failed induction. The systemic side effects (shivering, diarrhoea, vomiting and pyrexia) were more common with oral misoprostol (44.5%) compared to vaginal misoprostol (20%). This difference gives an overall Odds Ratio of 2.2 at 95% Cl of 1.6-2.8(p < 0.05).


CONCLUSIONS
Vaginal misoprostol achieved successful induction of labour in women with IUFD in a shorter time than oral misoprostol with significantly less side effects.
Nyende
L
L
Department of Obstetrics and Gynaecology, Medical University of Southern Africa (MEDUNSA), South Africa.
Towobola
O A
OA
Mabina
M H
MH
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage; D000282:Administration, Intravaginal; D000328:Adult; D005260:Female; D005313:Fetal Death; D005865:Gestational Age; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D008423:Maternal Age; D016595:Misoprostol / Q000008:administration & dosage*; D011247:Pregnancy; D011446:Prospective Studies; D013019:South Africa; D013997:Time Factors; D016896:Treatment Outcome; D014599:Uterus / Q000187:drug effects*
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol